Cover Image
市場調查報告書

類風濕性關節炎治療藥:各種技術和全球市場

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

出版商 BCC Research 商品編碼 364584
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎治療藥:各種技術和全球市場 Therapies for Rheumatoid Arthritis: Technologies and Global Markets
出版日期: 2016年07月27日 內容資訊: 英文 93 Pages
簡介

全球類風濕性關節炎治療藥的市場,預計從2015年到2020年以1.3%的年複合成長率發展,從2014年的190億美元,到2015年達199億美元,成長到2020年的213億美元的規模。

本報告提供全球類風濕性關節炎治療藥的市場調查,疾病概要與疾病的管理,診斷及治療趨勢與指南,主要國家的診斷簡介,主要的治療藥的市場規模的預測,未滿足需求與市場機會分析,開發平台趨勢,專利資料,企業簡介等彙整資料。

第1章 簡介

第2章 摘要

第3章 疾病概要

  • 病因
  • 病理生理學
  • 症狀
  • 預後
  • 生活品質
  • 流行病學
    • 疾病的背景
    • 風險因素、合併症

第4章 疾病管理

  • 診斷
    • ACR分類標準 (1987年)
    • ACR/EULAR新分類標準 (2010年)
  • 治療概要
    • ACR的推薦治療 (2012年)
    • ACR的RA治療指南 (2015年)
    • 初期RA的推薦治療
    • 非初期RA的推薦治療
    • 生物製藥、TOFACITINIB處方患者的DMARD類、TB篩檢臨床檢驗監測的推薦
    • EULAR的推薦治療(2013年)
    • 臨床性實踐
    • 診斷簡介
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
      • 日本
      • 澳洲
      • 中國
      • 印度
  • 生技仿製藥
  • 競爭分析
    • 概要

第5章 未滿足需求與市場機會

  • 未滿足需求
  • 差距分析
  • 市場機會

第6章 開發平台分析

第7章 專利分析

第8章 企業簡介

  • AB SCIENCE
  • ABBOTT LABORATORIES
  • AMGEN INC.
  • Astellas Pharma Inc.
  • BAXALTA INC.
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CELGENE CORP.
  • CELLTRION INC.
  • COHERUS BIOSCIENCES INC.
  • 第一三共
  • Eisai
  • ELI LILLY
  • Fuji Film Kyowa Kirin Biologics
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • JOHNSON & JOHNSON
  • KINETA INC.
  • MABTECH AB
  • MYCENAX BIOTECH INC.
  • NOVARTIS AG
  • 小野藥品工業
  • PFIZER
  • ROCHE
  • SAMSUNG BIOLOGICS CO. LTD.
  • 武田藥品工業
  • UCB GROUP/IMMUNOMEDICS

第9章 成長推進因素、障礙

圖表

目錄
Product Code: PHM072A

The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.

This report provides:

  • An overview of the global markets, therapies, and related technologies for treating Rheumatoid Arthritis (RA).
  • Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Discussion covering suppliers of therapeutic products for RA and analysis based on market share, product types, and geography (where data is available).
  • An overview of the disease including etiology, epidemiology, pathophysiology, risk factors and co-morbidities, and progression and outcomes.
  • An in-depth pipeline analysis, and biologic agents, both anti -TNF and non-TNF related currently under investigation or newly approved for use by the FDA are highlighted.
  • Relevant patent analysis.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF REPORT

The emphasis of this report is on the marketed products and also products in different stages of clinical development.

Special focus is placed on how new products and technologies will affect current market leaders in the RA treatment sector. Profiles are provided of companies projected to have products in the market during the forecast period and on companies with promising pipelines.

Profiles of the many emerging competitors in this sector provide a comprehensive assessment of the various products and technologies entering this market as well as marketing strategies being used to gain a competitive edge.

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the rheumatoid arthritis market. The key players are J&J, AbbVie, Pfizer, GSK, Eli Lilly, Diachii Sankyo, Bristol-Myers Squibb (BMS), Roche, etc.

ANALYST'S CREDENTIALS

Geeta Ogra Bedi has more than 17 years of global experience in the pharmaceutical and healthcare industries and is the Founder/Director of Providentia Research, a consulting firm that provides services in the area of auditing (PVG, GCP, GLP and GMP), medical writing and market research. She has worked with a variety of organizations internationally, ranging from contract research organizations and business partners to clinical sites, service providers and manufacturers. She led the quality assurance program for the directed studies and clinical development of an antimalarial is Asia and Africa. Geeta received an Appreciation Award from the President of India for exceptional contribution in the development of a new chemical entity (NCE), as well as an award for best poster at an international conference on Hypertension and Diabetes. She received her Bachelor's degree in Pharmacy and her Master's in Pharmacy/Pharmacology in New Delhi, India.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS, BY THERAPEUTIC CLASS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS BY THERAPEUTIC CLASS, 2014-2020 ($ MILLIONS)
  • SUMMARY TABLE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, 2014-2020 ($ MILLIONS)

CHAPTER 3 DISEASE OVERVIEW

  • ETIOLOGY
  • PATHOPHYSIOLOGY
  • SYMPTOMS
  • TABLE 1 COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
  • PROGNOSIS
  • QUALITY OF LIFE
  • EPIDEMIOLOGY
    • DISEASE BACKGROUND
    • TABLE 2 EPIDEMIOLOGICAL FORECAST FOR DIAGNOSED PREVALENT CASES OF RHEUMATOID ARTHRITIS, BY REGION, THROUGH 2020 (NO.)
    • RISK FACTORS AND COMORBIDITIES
    • TABLE 3 RISK FACTORS AND COMORBIDITIES FOR RHEUMATOID ARTHRITIS

CHAPTER 4 DISEASE MANAGEMENT

  • DIAGNOSIS
    • 1987 ACR RA DIAGNOSTIC CRITERIA
    • TABLE 4 THE 1987 ACR DIAGNOSTIC CRITERIA FOR RA
    • 2010 ACR/EULAR RA DIAGNOSTIC CRITERIA
    • TABLE 5 THE 2010 ACR/EULAR DIAGNOSTIC CRITERIA FOR RA
  • TREATMENT OVERVIEW
  • TABLE 6 TREATMENT GUIDELINES FOR RA
    • ACR 2012 RECOMMENDATIONS FOR THE TREATMENT OF RA
    • TABLE 7 THE ACR 2012 CRITERIA FOR RA REMISSION, AND LOW, MODERATE, AND HIGH DISEASE ACTIVITY
    • TABLE 8 THE ACR/EULAR 2011 CRITERIA FOR RA REMISSION USED IN THE 2013 UPDATE TO THE EULAR RECOMMENDATIONS FOR RA MANAGEMENT
    • FIGURE 1 FLOWCHART FOR THE MANAGEMENT OF RA IN EARLY DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
    • FIGURE 2 FLOWCHART FOR THE MANAGEMENT OF RA IN ESTABLISHED DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
    • 2015 ACR GUIDELINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    • RECOMMENDATIONS FOR THE TREATMENT OF PATIENTS WITH EARLY RA
    • TABLE 9 RECOMMENDATIONS FOR PATIENTS WITH SYMPTOMATIC EARLY RA
    • FIGURE 3 RECOMMENDATIONS FOR TREATMENT OF EARLY RA
    • RECOMMENDATIONS FOR THE TREATMENT OF PATIENTS WITH ESTABLISHED RA
    • TABLE 10 RECOMMENDATIONS FOR OPTIMAL FOLLOWUP LABORATORY MONITORING INTERVALS*
    • RECOMMENDATIONS FOR LABORATORY MONITORING FOR DMARDS AND TB SCREENING IN PATIENTS RECEIVING BIOLOGICS OR TOFACITINIB
    • EULAR 2013 RECOMMENDATIONS FOR THE TREATMENT OF RA
    • FIGURE 4 FLOWCHART FOR THE MANAGEMENT OF PATIENTS WITH RA, ACCORDING TO THE 2013 EULAR RECOMMENDATIONS
    • TABLE 11 MOSTMOST PRESCRIBED BIOLOGICS FOR THE TREATMENT OF RA (AFTER CSDMARDS), BY REGION
    • TABLE 12 MINOR THERAPEUTIC DRUG CLASSES USED TO TREAT RA
    • CLINICAL PRACTICE
    • TABLE 13 RA DIAGNOSIS PROFILE IN THE U.S.
      • France
      • TABLE 14 RA DIAGNOSIS PROFILE IN FRANCE
      • Germany
      • TABLE 15 RA DIAGNOSIS PROFILE IN GERMANY
      • Italy
      • TABLE 16 RA DIAGNOSIS PROFILE IN ITALY
      • Spain
      • TABLE 17 RA DIAGNOSIS PROFILE IN SPAIN
      • U.K.
      • TABLE 18 RA DIAGNOSIS PROFILE IN THE UK
      • Japan
      • TABLE 19 RA DIAGNOSIS PROFILE IN JAPAN
      • Australia
      • TABLE 20 RA DIAGNOSIS PROFILE IN AUSTRALIA
      • China
      • TABLE 21 RA DIAGNOSIS PROFILE IN CHINA
      • India
      • TABLE 22 RA DIAGNOSIS PROFILE IN INDIA
      • TABLE 23 LEADING DRUGS FOR TREATMENT OF RA
  • BIOSIMILARS
  • TABLE 24 GLOBAL MARKET FOR MAJOR BIOSIMILARS BY REGION AND TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 25 GLOBAL MARKET FOR ENBREL, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR HUMIRA, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR REMICADE (INFLIXIMAB), BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR ACTEMRA, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR ORENCIA (ABATACEPT), BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR RITUXAN (MABTHERA), BY REGION, THROUGH 2020 ($ MILLIONS)
  • COMPETITIVE ASSESSMENT
    • OVERVIEW

CHAPTER 5 UNMET NEED AND OPPORTUNITY

  • UNMET NEED
  • GAP ANALYSIS
  • OPPORTUNITY

CHAPTER 6 PIPELINE ASSESSMENT

  • OVERVIEW 6
  • TABLE 31 LIST OF RA THERAPIES IN CLINICAL TRIALS, BY PHASE
  • TABLE 32 LIST OF RA THERAPIES IN DEVELOPMENT, BY PHASE

CHAPTER 7 PATENT ASSESSMENTS

  • TABLE 33 LIST OF THERAPIES FOR RA IN THE MARKET, BY PATENT EXPIRY DATE
  • TABLE 34 LIST OF PATENTS ISSUED FOR RA THERAPIES
  • TABLE 35 LIST OF PATENT APPLICATIONS FOR RA THERAPIES

CHAPTER 8 COMPANY PROFILES

  • AB SCIENCE
  • ABBOTT LABORATORIES
    • ABBVIE
  • AMGEN INC.
  • ASTELLAS
  • BAXALTA INC.
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CELGENE CORP.
  • CELLTRION INC.
  • COHERUS BIOSCIENCES INC.
  • DAIICHI SANKYO CO. LTD.
  • EISAI
  • ELI LILLY
  • FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD.
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • JOHNSON & JOHNSON
  • KINETA INC.
  • MABTECH AB
  • MYCENAX BIOTECH INC.
  • NOVARTIS AG
  • ONO PHARMACEUTICAL CO. LTD.
  • PFIZER
  • ROCHE
  • SAMSUNG BIOLOGICS CO. LTD.
  • TAKEDA PHARMACEUTICALS
  • UCB GROUP/IMMUNOMEDICS

CHAPTER 9 DRIVERS AND BARRIERS

  • TABLE 36 DRIVERS AND BARRIERS FOR RA THERAPIES
  • DRIVER: LAUNCH OF NOVEL DRUGS, INCLUDING ORAL JAK INHIBITORS AND NOVEL BIOLOGICS FOR RA
  • DRIVER: EARLIER DIAGNOSIS AND TREATMENT
  • DRIVER: MARKET ENTRY OF BIOSIMILARS WILL BRING A THERAPY OPTION FOR THOSE WHO CANNOT AFFORD BRANDED BIOLOGICS
  • DRIVER: AGING POPULATION AND INCREASING PREVALENT CASES OF RA
  • BARRIER: EFFORTS TO REDUCE COSTS IN THE TREATMENT OF RA
  • BARRIER: LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
  • BARRIER: ENTRY OF BIOSIMILARS WILL CREATE A LESS EXPENSIVE TREATMENT ALTERNATIVE

LIST OF TABLES

  • SUMMARY TABLE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS, BY THERAPEUTIC CLASS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY TABLE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
  • TABLE 2 EPIDEMIOLOGICAL FORECAST FOR DIAGNOSED PREVALENT CASES OF RHEUMATOID ARTHRITIS, BY REGION, THROUGH 2020 (NO.)
  • TABLE 3 RISK FACTORS AND COMORBIDITIES FOR RHEUMATOID ARTHRITIS
  • TABLE 4 THE 1987 ACR DIAGNOSTIC CRITERIA FOR RA
  • TABLE 5 THE 2010 ACR/EULAR DIAGNOSTIC CRITERIA FOR RA
  • TABLE 6 TREATMENT GUIDELINES FOR RA
  • TABLE 7 THE ACR 2012 CRITERIA FOR RA REMISSION, AND LOW, MODERATE, AND HIGH DISEASE ACTIVITY
  • TABLE 8 THE ACR/EULAR 2011 CRITERIA FOR RA REMISSION USED IN THE 2013 UPDATE TO THE EULAR RECOMMENDATIONS FOR RA MANAGEMENT
  • TABLE 9 RECOMMENDATIONS FOR PATIENTS WITH SYMPTOMATIC EARLY RA
  • TABLE 10 RECOMMENDATIONS FOR OPTIMAL FOLLOWUP LABORATORY MONITORING INTERVALS*
  • TABLE 11 MOSTMOST PRESCRIBED BIOLOGICS FOR THE TREATMENT OF RA (AFTER CSDMARDS), BY REGION
  • TABLE 12 MINOR THERAPEUTIC DRUG CLASSES USED TO TREAT RA
  • TABLE 13 RA DIAGNOSIS PROFILE IN THE U.S.
  • TABLE 14 RA DIAGNOSIS PROFILE IN FRANCE
  • TABLE 15 RA DIAGNOSIS PROFILE IN GERMANY
  • TABLE 16 RA DIAGNOSIS PROFILE IN ITALY
  • TABLE 17 RA DIAGNOSIS PROFILE IN SPAIN
  • TABLE 18 RA DIAGNOSIS PROFILE IN THE UK
  • TABLE 19 RA DIAGNOSIS PROFILE IN JAPAN
  • TABLE 20 RA DIAGNOSIS PROFILE IN AUSTRALIA
  • TABLE 21 RA DIAGNOSIS PROFILE IN CHINA
  • TABLE 22 RA DIAGNOSIS PROFILE IN INDIA
  • TABLE 23 LEADING DRUGS FOR TREATMENT OF RA
  • TABLE 24 GLOBAL MARKET FOR MAJOR BIOSIMILARS BY REGION AND TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 25 GLOBAL MARKET FOR ENBREL, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR HUMIRA, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR REMICADE (INFLIXIMAB), BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR ACTEMRA, BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR ORENCIA (ABATACEPT), BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR RITUXAN (MABTHERA), BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 LIST OF RA THERAPIES IN CLINICAL TRIALS, BY PHASE
  • TABLE 32 LIST OF RA THERAPIES IN DEVELOPMENT, BY PHASE
  • TABLE 33 LIST OF THERAPIES FOR RA IN THE MARKET, BY PATENT EXPIRY DATE
  • TABLE 34 LIST OF PATENTS ISSUED FOR RA THERAPIES
  • TABLE 35 LIST OF PATENT APPLICATIONS FOR RA THERAPIES
  • TABLE 36 DRIVERS AND BARRIERS FOR RA THERAPIES

LIST OF FIGURES

  • SUMMARY FIGURE A GLOBAL MARKET FOR THERAPIES FOR RHEUMATOID ARTHRITIS BY THERAPEUTIC CLASS, 2014-2020 ($ MILLIONS)
  • SUMMARY FIGURE B GLOBAL MARKET FOR THERAPEUTIC PRODUCTS FOR RHEUMATOID ARTHRITIS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 1 FLOWCHART FOR THE MANAGEMENT OF RA IN EARLY DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
  • FIGURE 2 FLOWCHART FOR THE MANAGEMENT OF RA IN ESTABLISHED DISEASE, ACCORDING TO THE ACR2012 RECOMMENDATIONS
  • FIGURE 3 RECOMMENDATIONS FOR TREATMENT OF EARLY RA
  • FIGURE 4 FLOWCHART FOR THE MANAGEMENT OF PATIENTS WITH RA, ACCORDING TO THE 2013 EULAR RECOMMENDATIONS
Back to Top